ArticleERJ open research2026
A study protocol for a randomised controlled trial of two stepwise pharmacological treatment approaches to adult asthma: inhaled corticosteroid/formoterol reliever-
Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: No randomised controlled trials (RCTs) have compared inhaled corticosteroid (ICS)/formoterol reliever-based stepwise algorithms with short-acting β-agonist (SABA) reliever-based stepwise algorithms, titrated to levels of asthma control and exacerbations. Knowledge gaps remain in understanding ICS exposure over time, transitions between treatment steps, efficacy and participant satisfaction with different algorithm approaches. Objective: The aim of the study is to determine the exposure to ICS in adults and adolescents aged 16 to 75 years treated with a budesonide/formoterol reliever-based algorithm (Algorithm 1) compared to a salbutamol reliever-based algorithm (Algorithm 2) across the spectrum of asthma severity. Methods: This is an investigator-initiated, 52-week, single-site, open-label, parallel-groups, 2-arm RCT of 152 adults and adolescents with mild, moderate and moderate-severe asthma (ACTRN12624001488594). Participants will be randomly allocated in a 1:1 ratio to a budesonide/formoterol reliever-based or a salbutamol reliever-based algorithm. Global Initiative for Asthma (GINA) treatment step at enrolment according to the 2024 GINA Guidelines will be used to allocate participants to the corresponding steps of each algorithm. Treatment step transition will be in response to asthma exacerbations and level of asthma control. Those experiencing exacerbations or poorly controlled asthma will be stepped up, and those well controlled stepped down. The primary outcome is ICS exposure. Important secondary outcomes include composite systemic corticosteroid exposure, rates of asthma exacerbations, asthma control, T-helper 2 biomarkers, spirometry and participants' treatment perceptions and satisfaction. Conclusion: This is the first RCT to compare ICS/formoterol- and SABA-based reliever stepwise algorithmic approaches in asthma, with treatment adjusted according to asthma control and exacerbations.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.